5th Stanford Drug Discovery Symposium (SDDS 2021) held virtually this year! April 19 - 20, 2021. Free registration!

STANFORD, CA, USA, March 22, 2021 -- Featuring talks from drug discovery leaders the Stanford Drug Discovery Symposium, April 19-20, 2021, is a free, virtual symposium hosted by Stanford University. This event offers an exciting opportunity for the public to hear about how drug research and development is done in the US and globally. Esteemed guests are from of major pharmaceutical companies, federal policy makers, venture capitalists, start-up companies, and scientists making groundbreaking advances. This year also offers a look into how COVID-19 has led to change in these spaces. Register for free at http://tinyurl.com/SDDS2021.

This year's SDDS "Lifetime Achievement Award" will be warded to Doug Lowy, MD, Principal Deputy Director, National Cancer Institute and John Schiller, PhD, Deputy Chief, Laboratory of Cellular Oncology, for their work on the HPV vaccine!

To view our list of esteemed speakers, and for more information visit: http://tinyurl.com/SDDS2021.

For sponsorship and press inquiries, contact preston@stanford.edu.

SDDS 2021 is sponsored in part by: Alexandria Ventures, Cytokinetics, Khloris Biosciences, Merck, OptinaDX, REGENXBIO Inc., Stanford Cancer Institute, Stanford Cardiovascular Institute, Santen, Novo Nordisk, Stanford Cardiovascular Health, Vala Sciences, Codex DNA, Servier BioInnovation, and 10X Genomics
Media Sponsors include: Biocom California, Keystone Symposia, and California Life Sciences

265 Campus Drive West
G1120, MC-5454
Stanford, CA 94305 USA

Press: David Preston: preston@stanford.edu

Stanford Medicine is an academic medical center with a three-part mission: research, teaching, and clinical care. While the academic portion (research and teaching) is core to the university’s mission, excellence in the clinical practice of medicine is inextricably intertwined with and essential for success in the other parts in the mission of an academic medical center. Without that academic component, there is no reason for us to have a clinical enterprise.

This release was published on openPR.